Patent ID: 6201168
Filing Date: 2001-03-13
Classification: A01K,A61K,C07K,C12N

Abstract:
A transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous .beta.-sarcoglycan gene, wherein said homozygous disruption prevents the expression of a functional .beta.-sarcoglycan protein in cells of the mouse, and wherein said homozygous disruption results in said transgenic knockout mouse exhibiting conditions of: (i) a reduced amount of .delta.-and .epsilon.-sarcoglycan, sarcospan and .alpha.-dystroglycan in a smooth muscle, (ii) a disruption of the sarcoglycan-sarcospan complex in a smooth muscle, and (iii) a reduced amount of sarcospan and .alpha.-, .gamma.-, -.delta., and .epsilon.-sarcoglycan in the sarcolemma of a skeletal and a cardiac muscle, compared to the amounts of .delta.-and .epsilon.-sarcoglycan, sarcospan and .alpha.-dystroglycan in the smooth muscles, the sarcoglycan-sarcospan complex in the smooth muscles, and sarcospan and .alpha.-, .gamma.-, -.delta., and .epsilon.-sarcoglycan in the sarcolemma of the skeletal and cardiac muscles of a wild type mouse, and wherein said homozygous disruption results in ischemia in said transgenic knockout mouse.